Pages that link to "Q46337884"

The following pages link to Delivery outcome in relation to maternal use of some recently introduced antidepressants (Q46337884):

Displaying 45 items.

• A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight (Q24623163) (← links)
• The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? (Q26741187) (← links)
• Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation (Q26795384) (← links)
• Antidepressant use in pregnancy: a critical review focused on risks and controversies (Q28281407) (← links)
• Live and non-live pregnancy outcomes among women with depression and anxiety: a population-based study (Q28482636) (← links)
• Prenatal antidepressant exposure: clinical and preclinical findings (Q30415540) (← links)
• On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. (Q33562778) (← links)
• Treatment considerations for patients with neuropathic pain and other medical comorbidities (Q33747271) (← links)
• Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. (Q33896573) (← links)
• Antidepressant use in pregnant and postpartum women (Q34068023) (← links)
• Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges (Q34237681) (← links)
• Pharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview (Q34250131) (← links)
• Neonatal adaptation in infants prenatally exposed to antidepressants--clinical monitoring using Neonatal Abstinence Score (Q34445231) (← links)
• Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. (Q34516341) (← links)
• Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study (Q34702282) (← links)
• The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists (Q34981937) (← links)
• Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis (Q35132422) (← links)
• Mother-infant antidepressant concentrations, maternal depression, and perinatal events (Q35172179) (← links)
• Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction (Q35506589) (← links)
• Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. (Q35794715) (← links)
• Maternal Use of Selective Serotonin Reuptake Inhibitors and Lengthening of the Umbilical Cord: Indirect Evidence of Increased Foetal Activity-A Retrospective Cohort Study (Q36002891) (← links)
• Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study (Q36045075) (← links)
• Cardiac dysfunction and prenatal exposure to venlafaxine (Q36797574) (← links)
• More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation. (Q37334235) (← links)
• Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort (Q37612128) (← links)
• Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Major and Cardiovascular Malformations: An Update (Q37777007) (← links)
• Drug treatment for mood disorders in pregnancy (Q37810766) (← links)
• Adverse reactions to duloxetine in depression (Q37872294) (← links)
• Antidepressant use in pregnancy (Q37872295) (← links)
• The use of antidepressants in pregnancy: focus on maternal risks. (Q38375187) (← links)
• The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review (Q38382317) (← links)
• Use of psychotropic drugs during pregnancy and breast-feeding. (Q38582061) (← links)
• The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies (Q38672603) (← links)
• Depression During Pregnancy and Postpartum. (Q38734781) (← links)
• Prenatal exposure to antidepressants and risk of epilepsy in childhood (Q40498883) (← links)
• Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth (Q43289832) (← links)
• Use of escitalopram during pregnancy: navigating towards international guidelines and the real world (Q46327865) (← links)
• Pregnancy Outcomes in Maternal Neuropsychiatric Illness and Substance Abuse (Q47160719) (← links)
• Maternal exposure to benzodiazepine and risk of preterm birth and low birth weight: A case-control study using a claims database in Japan (Q47172073) (← links)
• Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women (Q47743073) (← links)
• The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists (Q57696679) (← links)
• Gebelikte Psikotrop İlaç Kullanımı: Bir Güncelleme (Q57820341) (← links)
• Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children (Q60667230) (← links)
• Current awareness: pharmacoepidemiology and drug safety (Q81407191) (← links)
• Antepartum depression: prevalence, diagnosis and treatment (Q82731633) (← links)